Navigating key news stories in pharma

Featured Stories

Featured
How Demand for Flexibility is Shaping Facilities of the Future
Strategy
How Demand for Flexibility is Shaping Facilities of the Future
Strategy

For decades, successful pharmaceutical manufacturing has been judged on scale. Nowadays, higher precedence is being given to speed, coping with complexity, and customization.

Read More →
Strategy
News
Amgen Further Commits to U.S. Manufacturing with Ohio Investment
Expansion
Amgen Further Commits to U.S. Manufacturing with Ohio Investment
Expansion

This latest investment into expanding its manufacturing capabilities reinforces the company’s commitment to the U.S. and enhances its global biomanufacturing network.

Expansion
PCI Expands U.S. Fill/Finish Capabilities with Althea Acquisition
Expansion
PCI Expands U.S. Fill/Finish Capabilities with Althea Acquisition
Expansion

The acquisition will provide PCI with a large-scale manufacturing hub on the West Coast of the U.S., complementing its existing global facilities.

Expansion
Granite Bio Emerges from Stealth to Advance Immunology Pipeline
Expansion
Granite Bio Emerges from Stealth to Advance Immunology Pipeline
Expansion

Significant funds, in series A & B funding rounds, have been raised from leading investors to advance the company’s two first-in-class monoclonal antibodies targeting inflammation, autoimmunity, and fibrosis.

Expansion
Advertise with TPN
Subscribe to TPN

Dealmaking

Featured
Granules India Acquires Senn Chemicals to Expand into Peptide Therapeutics
Granules India Acquires Senn Chemicals to Expand into Peptide Therapeutics

Pharmaceutical company, Granules India, has acquired Swiss CDMO, Senn Chemicals AG, for CHF 20 million (USD22 million) through its subsidiary, Granules Peptides as it enters the peptide therapeutics sector.

PharmaLogic Strengthens Footing in Radiopharmaceutical Field with Acquisition
PharmaLogic Strengthens Footing in Radiopharmaceutical Field with Acquisition

The radiopharmaceuticals CDMO will have a majority stake in Agilera Pharma, advancing its strategy of becoming a fully-integrated service provider in the radiopharmaceutical therapy sector.

SHL Medical and Kindeva Partner to Enhance Molly® Autoinjector Platform
SHL Medical and Kindeva Partner to Enhance Molly® Autoinjector Platform

Drug delivery companies — SHL Medical and Kindeva Drug Delivery — have formed a partnership to enhance SHL Medical’s Molly® autoinjector platform aimed at pharmaceutical and biotechnology companies.

Porton Advanced and Eureka Therapeutics Partner to Accelerate T-Cell Therapy Development
Porton Advanced and Eureka Therapeutics Partner to Accelerate T-Cell Therapy Development

Advanced therapy medicinal products specialist CDMO, Porton Advanced, and clinical-stage biotech, Eureka Therapeutics, have entered a strategic collaboration to accelerate the development and commercialization of T-cell therapies for cancer treatment.

Future Biopharma

Featured
Syntegon Launches New Filling Machine for RTU Syringes
Syntegon Launches New Filling Machine for RTU Syringes

The company’s MLD Advanced uses a combination of proven technologies to enable manufacturers to quickly and efficiently meet the requirements of high outputs.

India: The Next Frontier in Global CDMO Services?
India: The Next Frontier in Global CDMO Services?

India’s pharmaceutical industry has long been synonymous with cost-effective pharmaceutical manufacturing - particularly when it comes to generic drugs. In recent years, India has been making a significant shift from low-cost generic drug production into CDMO services.

Is North America's Hold on the Biologics CDMO Market at Risk?
Is North America's Hold on the Biologics CDMO Market at Risk?

The global biologics market is expected to reach USD 720 bn by 2030 - fueled by the increasing demand for biologics, biosimilars, and advanced therapies - and is undoubtedly an area of keen interest for CDMOs specializing in biologics.

Five Trends That Will Redefine the CDMO Industry in 2025
Five Trends That Will Redefine the CDMO Industry in 2025

The CDMO industry saw significant growth in 2024, as biotech and pharmaceutical companies continued the trend toward outsourcing R&D activities. This surge was evident in the global CDMO market value, which ended the year with a valuation of USD 185 billion.

R&D

Featured
Accure Therapeutics Granted USD 1.6 Million to Advance Parkinson’s Drug Candidate
Accure Therapeutics Granted USD 1.6 Million to Advance Parkinson’s Drug Candidate

The Michael J. Fox Foundation for Parkinson’s Research and the Luxembourg National Research Fund have provided funding for two separate projects assessing Accure Therapeutics’ ACT-02 for the treatment of Parkinson’s disease.

New Analysis Strengthens Evidence of Reduced Risk of Dementia with Shingles Vaccination
New Analysis Strengthens Evidence of Reduced Risk of Dementia with Shingles Vaccination

Through analysis of historical vaccination program data, researchers have demonstrated a persistent link between the live-attenuated zoster vaccination and a lower incidence of dementia.

BioDuro Opens New Laboratory in Shanghai for Highly Potent Compound Synthesis
BioDuro Opens New Laboratory in Shanghai for Highly Potent Compound Synthesis

BioDuro, the global contract research, development and manufacturing (CRDMO) company, has opened a new state-of-the-art laboratory in Shanghai, China for the synthesis of high-potency APIs for the pharmaceutical industry.

Novartis’ Rare Kidney Disease Candidate Gains Positive EU Committee Opinion
Novartis’ Rare Kidney Disease Candidate Gains Positive EU Committee Opinion

Novartis' Fabhalta® (iptacopan), an oral drug targeting the alternative complement pathway, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for treating a rare kidney disease in adults, C3 glomerulopathy (C3G).

Expansion

Featured
Amgen Further Commits to U.S. Manufacturing with Ohio Investment
Amgen Further Commits to U.S. Manufacturing with Ohio Investment

This latest investment into expanding its manufacturing capabilities reinforces the company’s commitment to the U.S. and enhances its global biomanufacturing network.

PCI Expands U.S. Fill/Finish Capabilities with Althea Acquisition
PCI Expands U.S. Fill/Finish Capabilities with Althea Acquisition

The acquisition will provide PCI with a large-scale manufacturing hub on the West Coast of the U.S., complementing its existing global facilities.

Granite Bio Emerges from Stealth to Advance Immunology Pipeline
Granite Bio Emerges from Stealth to Advance Immunology Pipeline

Significant funds, in series A & B funding rounds, have been raised from leading investors to advance the company’s two first-in-class monoclonal antibodies targeting inflammation, autoimmunity, and fibrosis.

Roche Commits Billions to Strengthening U.S. Presence
Roche Commits Billions to Strengthening U.S. Presence

Over the next five years, Roche will invest USD 50 billion to expand and upgrade existing facilities and build new facilities across its Pharmaceutical and Diagnostics Division in the U.S.

Strategy

Featured
Navigating the Hot Topics for Bio/pharma
Navigating the Hot Topics for Bio/pharma

As the bio/pharma industry faces the looming threat of tariffs, it is clearer than ever that reporting on the key issues and trends set to shape industry is imperative to help stakeholders stay informed.

How Demand for Flexibility is Shaping Facilities of the Future
How Demand for Flexibility is Shaping Facilities of the Future

For decades, successful pharmaceutical manufacturing has been judged on scale. Nowadays, higher precedence is being given to speed, coping with complexity, and customization.

AmplifyBio Shuts Down Operations
AmplifyBio Shuts Down Operations

A challenging biotech investment landscape is shaking up the industry and having a negative impact on multiple CDMOs in the space.

Novartis is Expanding its U.S. Manufacturing and R&D Presence
Novartis is Expanding its U.S. Manufacturing and R&D Presence

Over the next five years, Novartis will be investing USD23 billion in 10 facilities, including seven new facilities.

Regulatory

Featured
Amgen’s UPLIZNA Gains FDA Nod for Rare Inflammatory Disease Indication
Amgen’s UPLIZNA Gains FDA Nod for Rare Inflammatory Disease Indication

The monoclonal antibody therapy is now the first and only treatment approved for patients with IgG4-RD.

Terumo’s Ultimaster™ Stents Gain MDR Approval for High-Bleeding Risk Patients
Terumo’s Ultimaster™ Stents Gain MDR Approval for High-Bleeding Risk Patients

Medical technology company, Terumo, has announced that it has received Medical Device Regulation (MDR) approval for an expanded indication of its Ultimaster Nagomi™ and Ultimaster™ Tansei™ stent systems.

J&J Sues Samsung Bioepis Over Biosimilar Breach
J&J Sues Samsung Bioepis Over Biosimilar Breach

Johnson & Johnson (J&J) has filed a lawsuit against Samsung Bioepis, alleging a breach of their 2023 agreement concerning the launch of Pyzchiva, a biosimilar to J&J's Stelara. The dispute centers on Samsung's attempt to sublicense Pyzchiva to a private-label distributor, a move J&J contends violates their settlement terms.

Merck Faces Keytruda Price Cuts Under IRA by 2028
Merck Faces Keytruda Price Cuts Under IRA by 2028

Merck expects its leading cancer drug, Keytruda, to be included in government price negotiations under the IRA starting in 2026 as its U.S. patent expires at the end of 2028. In 2024, Keytruda accounted for 46% of Merck’s total sales, and Merck’s CEO has expressed that price-setting via Medicare could limit the development of new therapies.

Upcoming Events

Featured
AACR Annual Meeting 2025

The AACR Annual Meeting is the critical driver of progress against cancer, the place where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share and discuss the latest breakthroughs.

Cell Culture Engineering XIX 2025

Since its beginning in 1988, the Cell Culture Engineering Conference series has been a very influential forum for leaders and experts from academic, regulatory, and industrial backgrounds to convene and discuss cell culture and related advancements that impact a growing spectrum of modalities.

Analytical Development Summit 2025

At this pivotal moment, the 4th ADC Analytical Development Summit returns to the World ADC Event Series, bringing together experts to address the unique analytical challenges of antibody-drug conjugates to help you navigate an increasingly crowded industry.

Microbiome & Probiotics R&D and Business Collaboration Forum 2025

The 13th Microbiome & Probiotics R&D and Business Collaboration Forum is confirmed to be held on April 28-29 2025 in The Netherlands. It will be co-located with the 7th Skin Microbiome & Cosmeceuticals Congress.